These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 7087954)
41. [Antibodies to acetylcholine receptor. Diagnosis and therapeutic interest in myasthenia gravis (author's transl)]. de Crousaz G Ann Chir; 1980 Mar; 34(3):188-92. PubMed ID: 7369693 [No Abstract] [Full Text] [Related]
42. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Losen M; MartÃnez-MartÃnez P; Phernambucq M; Schuurman J; Parren PW; De Baets MH Ann N Y Acad Sci; 2008; 1132():174-9. PubMed ID: 18567867 [TBL] [Abstract][Full Text] [Related]
43. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Lee SW; Sullenger BA Nat Biotechnol; 1997 Jan; 15(1):41-5. PubMed ID: 9035104 [TBL] [Abstract][Full Text] [Related]
44. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis. Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243 [TBL] [Abstract][Full Text] [Related]
45. Interaction of human antibody and murine monoclonal antibody with muscle acetylcholine receptor. Dwyer DS; Kearney JF; Bradley RJ; Kemp GE; Oh SJ Ann N Y Acad Sci; 1981; 377():143-57. PubMed ID: 6951469 [No Abstract] [Full Text] [Related]
46. Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture. Sideris S; Lagoumintzis G; Kordas G; Kostelidou K; Sotiriadis A; Poulas K; Tzartos SJ J Neuroimmunol; 2007 Sep; 189(1-2):111-7. PubMed ID: 17617475 [TBL] [Abstract][Full Text] [Related]
47. [Anesthetic considerations for thymectomy in a patient having an anti-acetylcholine receptor antibody without myasthenia gravis]. Koshida T; Hara K; Obara G; Sata T Masui; 2008 Aug; 57(8):993-5. PubMed ID: 18710007 [TBL] [Abstract][Full Text] [Related]
48. Genetic and antibody-mediated channelopathies at the neuromuscular junction. Vincent A; Mills K Electroencephalogr Clin Neurophysiol Suppl; 1999; 50():250-8. PubMed ID: 10689470 [No Abstract] [Full Text] [Related]
49. [Plasma exchange in myasthenia gravis]. Redeker M; Meyer-Wahl L Nervenarzt; 1982 Dec; 53(12):729-32. PubMed ID: 7155236 [No Abstract] [Full Text] [Related]
50. Myasthenia gravis: an example of receptor disease. Conti-Tronconi BM; Fumagalli G; Scotti A; Brigonzi A; Sher E; Morgutti M; Clementi F Adv Biochem Psychopharmacol; 1980; 21():473-88. PubMed ID: 7376974 [No Abstract] [Full Text] [Related]
57. [Antibodies in myasthenia gravis]. Eymard B Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288 [TBL] [Abstract][Full Text] [Related]
58. Autoantibodies to receptors by an autoantiidiotypic route. Erlanger BF; Cleveland WL; Wassermann NH; Ku HH; Hill BL; Sarangarajan R; Penn AS Ann N Y Acad Sci; 1987; 505():416-22. PubMed ID: 3500668 [No Abstract] [Full Text] [Related]